Limits...
Involvement of adrenoceptors, dopamine receptors and AMPA receptors in antidepressant-like action of 7-O-ethylfangchinoline in mice.

Sheng ZF, Cui XY, Cui SY, Yu B, Zhang XQ, Li SJ, Cao Q, Huang YL, Xu YP, Song JZ, Ding H, Lin ZG, Yang G, Zhang YH - Acta Pharmacol. Sin. (2015)

Bottom Line: YH-200 (60 mg/kg) significantly decreased the immobility time in both FST and TST, and prolonged the latency to immobility in FST.In contrast, pretreatment with α2 adrenoceptor antagonist yohimbine (1 mg/kg) augmented the antidepressant-like action of YH-200 (30 mg/kg) in FST.Chronic administration of YH-200 (30 and 60 mg/kg for 14 d) did not produce drug tolerance; instead its antidepressant-like action was strengthened.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, School of Basic Medical Science, Peking University, Beijing 100191, China.

ABSTRACT

Aim: 7-O-ethylfangchinoline (YH-200) is a bisbenzylisoquinoline derivative. The aim of this study was to investigate the antidepressant-like action and underlying mechanisms of YH-200 in mice.

Methods: Mice were treated with YH-200 (15, 30, and 60 mg/kg, ig) or tetrandrine (30 and 60 mg/kg, ig) before conducting forced swimming test (FST), tail suspension test (TST), or open field test (OFT).

Results: YH-200 (60 mg/kg) significantly decreased the immobility time in both FST and TST, and prolonged the latency to immobility in FST. YH-200 (60 mg/kg) was more potent than the natural bisbenzylisoquinoline alkaloid tetrandrine (60 mg/kg) in FST. Pretreatment with α1-adrenoceptor antagonist prazosin (1 mg/kg), β-adrenoceptor antagonist propranolol (2 mg/kg), dopamine D1/D5 receptor antagonist SCH23390 (0.05 mg/kg), dopamine D2/D3 receptor antagonist haloperidol (0.2 mg/kg) or AMPA receptor antagonist NBQX (10 mg/kg) prevented the antidepressant-like action of YH-200 (60 mg/kg) in FST. In contrast, pretreatment with α2 adrenoceptor antagonist yohimbine (1 mg/kg) augmented the antidepressant-like action of YH-200 (30 mg/kg) in FST. Chronic administration of YH-200 (30 and 60 mg/kg for 14 d) did not produce drug tolerance; instead its antidepressant-like action was strengthened. Chronic administration of YH-200 did not affect the body weight of mice compared to control mice.

Conclusion: YH-200 exerts its antidepressant-like action in mice via acting at multi-targets, including α1, α2 and β-adrenoceptors, D1/D5 and D2 /D3 receptors, as well as AMPA receptors.

No MeSH data available.


Effects of administration of YH-200 for 14 d on immobility time in the mouse FST (A) and body weight variation (B). Values are expressed as the mean±SEM. cP<0.01 vs control group. n=10/group.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4564886&req=5

fig5: Effects of administration of YH-200 for 14 d on immobility time in the mouse FST (A) and body weight variation (B). Values are expressed as the mean±SEM. cP<0.01 vs control group. n=10/group.

Mentions: As shown in Figure 5A, 14-d administration of YH-200 significantly reduced the immobility time even at the lower dose of 30 mg·kg-1·d-1 and the 60 mg·kg-1·d-1 dose (F(2,27)=17.85, P<0.0001) in the FST. However, there were no significant differences in body weight among all groups (Figure 5B).


Involvement of adrenoceptors, dopamine receptors and AMPA receptors in antidepressant-like action of 7-O-ethylfangchinoline in mice.

Sheng ZF, Cui XY, Cui SY, Yu B, Zhang XQ, Li SJ, Cao Q, Huang YL, Xu YP, Song JZ, Ding H, Lin ZG, Yang G, Zhang YH - Acta Pharmacol. Sin. (2015)

Effects of administration of YH-200 for 14 d on immobility time in the mouse FST (A) and body weight variation (B). Values are expressed as the mean±SEM. cP<0.01 vs control group. n=10/group.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4564886&req=5

fig5: Effects of administration of YH-200 for 14 d on immobility time in the mouse FST (A) and body weight variation (B). Values are expressed as the mean±SEM. cP<0.01 vs control group. n=10/group.
Mentions: As shown in Figure 5A, 14-d administration of YH-200 significantly reduced the immobility time even at the lower dose of 30 mg·kg-1·d-1 and the 60 mg·kg-1·d-1 dose (F(2,27)=17.85, P<0.0001) in the FST. However, there were no significant differences in body weight among all groups (Figure 5B).

Bottom Line: YH-200 (60 mg/kg) significantly decreased the immobility time in both FST and TST, and prolonged the latency to immobility in FST.In contrast, pretreatment with α2 adrenoceptor antagonist yohimbine (1 mg/kg) augmented the antidepressant-like action of YH-200 (30 mg/kg) in FST.Chronic administration of YH-200 (30 and 60 mg/kg for 14 d) did not produce drug tolerance; instead its antidepressant-like action was strengthened.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, School of Basic Medical Science, Peking University, Beijing 100191, China.

ABSTRACT

Aim: 7-O-ethylfangchinoline (YH-200) is a bisbenzylisoquinoline derivative. The aim of this study was to investigate the antidepressant-like action and underlying mechanisms of YH-200 in mice.

Methods: Mice were treated with YH-200 (15, 30, and 60 mg/kg, ig) or tetrandrine (30 and 60 mg/kg, ig) before conducting forced swimming test (FST), tail suspension test (TST), or open field test (OFT).

Results: YH-200 (60 mg/kg) significantly decreased the immobility time in both FST and TST, and prolonged the latency to immobility in FST. YH-200 (60 mg/kg) was more potent than the natural bisbenzylisoquinoline alkaloid tetrandrine (60 mg/kg) in FST. Pretreatment with α1-adrenoceptor antagonist prazosin (1 mg/kg), β-adrenoceptor antagonist propranolol (2 mg/kg), dopamine D1/D5 receptor antagonist SCH23390 (0.05 mg/kg), dopamine D2/D3 receptor antagonist haloperidol (0.2 mg/kg) or AMPA receptor antagonist NBQX (10 mg/kg) prevented the antidepressant-like action of YH-200 (60 mg/kg) in FST. In contrast, pretreatment with α2 adrenoceptor antagonist yohimbine (1 mg/kg) augmented the antidepressant-like action of YH-200 (30 mg/kg) in FST. Chronic administration of YH-200 (30 and 60 mg/kg for 14 d) did not produce drug tolerance; instead its antidepressant-like action was strengthened. Chronic administration of YH-200 did not affect the body weight of mice compared to control mice.

Conclusion: YH-200 exerts its antidepressant-like action in mice via acting at multi-targets, including α1, α2 and β-adrenoceptors, D1/D5 and D2 /D3 receptors, as well as AMPA receptors.

No MeSH data available.